Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

Abstract

We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg (n = 5) or placebo (n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.

Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice

“…Prior to Res intervention, KKAy mice present with weight gain and increases in TG, TC, and LDL-C levels compared to C57BL/6 J mice, moreover, after 12 weeks, non-treated KKAy mice developed severe oxidative stress and metabolic disorders in liver, leading to the unfavorable decreases of liver enzymes such as GPx, which is consistent with previous study supporting these mice as proper animal model for investigation of lipid metabolic disorders [18]. In our study, we investigated the effect of Res on lipid metabolism via dietary Res treatment.…”

Oral Administration of Candesartan Improves the Survival of Mice with Viral Myocarditis through Modification of Cardiac Adiponectin Expression

“…Candesartan increases circulating adiponectin concentration in human [9,18] and in diabetic mice [11]. Candesartan also increases adiponectin mRNA in fat tissue in hypertensive rat [12].…”

Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin

“…It has been reported that candesartan increases circulating adiponectin concentrations in human [15] and in diabetic mice [16]. Candesartan also increases adiponectin mRNA of fat tissue in hypertensive rats [17].…”